Company: MDCXW
Filing Date: 2025-06-23
Form Type: PRER14A
Source: 0001062993-25-012067
Chunk: 7

Company: Medicus Pharma Ltd.
Filing Date: 2025-06-23
Form: PRER14A
Chunk 7
---
-290-1175</div>

If you are a Non-registered Shareholder and you wish to receive a separate set of proxy materials in the future, or if you have received multiple sets of proxy materials and would like to receive only one set in the future, please contact your bank or broker directly.

Shareholders also may write to, or email us, at the address below to request a separate copy of the proxy materials:

<div align='center'>Medicus Pharma Ltd.
Attn: Corporate Secretary
300 Conshohocken State Rd. Suite 200
W. Conshohocken, PA 19428
madesso@medicuspharma.com

- 9 -</div>

Who pays the cost of soliciting proxies for the Meeting?

The Company will bear the cost of solicitation, including the cost of preparing, printing and mailing the materials in connection with the solicitation of proxies. This solicitation of proxies is being made to Shareholders by mail but may be supplemented by telephone or other personal contact. The Company's officers and regular employees, on behalf of the Company without being additionally compensated, may solicit proxies personally and by mail, telephone, facsimile or electronic communication at nominal cost to the Company.

The Company will not reimburse Intermediaries such as brokerage houses and other custodians, nominees and fiduciaries for forwarding proxy materials to Non-registered Shareholders.

What items of business will be voted on at the Meeting?

The business items to be voted on at the Meeting are:

1.the appointment of KPMG LLP ("KPMG") as auditors for the Company and the authorization of the Board to fix the auditors' remuneration and terms of engagement;

2.the election of directors for the forthcoming year from the nominees proposed by the Board;

3.the confirmation and approval of the Quorum Amendment (as defined under the heading "Proposal 3 - Quorum Amendment");

4.the approval of the issuance of Common Shares pursuant to the pursuant to the Standby Equity Purchase Agreement, dated February 10, 2025 (the "SEPA") in accordance with the Nasdaq 20% Rule (as defined under the heading "Proposal 4 - Issuance of Shares Under Nasdaq 20% Rule");

5.a special resolution approving the Chairman Amendment (as defined under the heading "Proposal 5 - Articles of Amendment"); and

6.the transaction of such other business as may properly come before the Meeting or any adjournment(s) or postponement(s) thereof